Company news

Acurx Pharmaceuticals, Inc. news in 2023

Acurx Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

December 10, 2023

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update

November 13, 2023

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

November 1, 2023

Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update

October 24, 2023

Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

October 18, 2023

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

October 1, 2023

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

September 11, 2023

Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023

August 21, 2023

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update

August 13, 2023

Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update

July 23, 2023

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023

June 19, 2023

Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET

June 14, 2023

Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering

May 15, 2023

Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update

May 11, 2023

Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update

May 4, 2023

Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

April 18, 2023

FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference

April 10, 2023

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

March 15, 2023

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

March 5, 2023

Decks in 2023